



basaglar[®]

insulin glargine injection
100 Units/mL

The BASAGLAR ELEMENT 2 clinical study

Rosenstock J, Hollander P, Bhargava A, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus[®]) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). *Diabetes Obes Metab.* 2015;17:734-741.

Learn more and
register for updates at
BASAGLAR.com

INDICATION

BASAGLAR is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

LIMITATION OF USE

BASAGLAR is not recommended for the treatment of diabetic ketoacidosis.

SELECT IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

BASAGLAR is contraindicated during episodes of hypoglycemia, and in patients with hypersensitivity to insulin glargine or one of its excipients.

Please see Important Safety Information on pages 3 and 4,
and [Full Prescribing Information](#), including [Patient Information](#).



> ELEMENT 2 trial design^{1,2}



A 24-week phase 3, randomized, double-blind trial in 756 adult patients with type 2 diabetes who were either insulin-naïve and failed to achieve adequate glycemic control on at least 2 oral anti-diabetic medications (OAMs), or were already on Lantus[®] (insulin glargine injection) products (approved in the US or outside the US) along with 2 or more OAMs with adequate or inadequate glycemic control


PRIMARY ENDPOINT: noninferiority of BASAGLAR to Lantus products (approved in the US or outside the US) as measured by change in A1C from baseline at 24 weeks.

SECONDARY ENDPOINT: proportion of patients achieving A1C <7% at 24 weeks.

STARTING DOSE: The starting dose for all insulin-naïve patients was 10 U/day, while patients entering the study on U.S.- or non-U.S.-approved Lantus were randomized to either BASAGLAR or U.S.- or non-U.S.-approved Lantus at a dose equivalent to their prestudy U.S.- or non-U.S.-approved Lantus dose; BASAGLAR and U.S.- or non-U.S.-approved Lantus titration was patient-driven based on self-measured fasting plasma glucose with a target of ≤ 100 mg/dL¹

> Type 2 diabetes: comparable A1C results^{1,2}

Type 2 diabetes: change in A1C from baseline at 24 weeks



Difference of 0.052% (95% CI -0.070 to 0.175)
Noninferiority margin 0.4% and then 0.3%

*Three patients randomized to BASAGLAR did not receive study drug and were not included in the full analysis set. Observed A1C data at 24 weeks were available from 331 (88%) and 329 (87%) patients randomized to the BASAGLAR and US- or non-US-approved Lantus groups, respectively.

[†]Approved in the US or outside the US
CI=confidence interval; OAMs=oral anti-diabetic medications.

IMPORTANT NOTE ABOUT THESE RESULTS: A1C information in the chart above and bullet points below were derived from the BASAGLAR US Prescribing Information.² The published ELEMENT 2 study reported A1C reductions of -1.29% with BASAGLAR vs -1.34% with Lantus products (approved in the US or outside the US); reductions to A1C <7% in 49% of patients taking BASAGLAR and 53% of patients taking Lantus products (approved in the US or outside the US) and a baseline A1C of 8.34% in patients taking BASAGLAR.¹ These differences are due to rounding.

BASAGLAR vs Lantus products (approved in the US or outside the US): percentage of patients achieving A1C <7% at 24 weeks^{2*}

- 48.8% of patients taking BASAGLAR (n=376[†]; baseline A1C: 8.35%)
- 52.5% of patients taking Lantus products (approved in the US or outside the US) (n=380[†]; baseline A1C: 8.31%)

*Secondary endpoint.

[†]Full analysis set; n values represent maximum sample size.

Please see Important Safety Information on pages 3 and 4, [Full Prescribing Information](#), including [Patient Information](#).

> Adverse events



This trial was not designed to evaluate the relative safety between BASAGLAR and Lantus products (approved in the US or outside the US), and comparator adverse event rates are not an adequate basis for comparison of rates between the products.

BASAGLAR vs Lantus products (approved in the US or outside the US): severe symptomatic hypoglycemia over 24 weeks of treatment¹



*Full analysis set; n values reflect maximum sample size.

†Approved in the US or outside the US.

Hypoglycemia was the most commonly observed adverse reaction in patients using insulin, including BASAGLAR. Hypoglycemia was defined as blood glucose ≤ 3.9 mmol/L (≤ 70 mg/dL) or a sign or symptom associated with hypoglycemia. Severe symptomatic hypoglycemia was defined as an event with symptoms consistent with hypoglycemia that required assistance of another person, and was associated with either blood glucose levels below 50 mg/dL or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.¹²

Rates of reported hypoglycemia depend upon the definition of hypoglycemia used, diabetes type, insulin dose, intensity of glucose control, background therapies, and other intrinsic and extrinsic factors. For these reasons, comparing rates of hypoglycemia in clinical trials for BASAGLAR with the incidence of hypoglycemia for other products may be misleading, and may not be representative of hypoglycemia rates that will occur in clinical practice.

Type 2 diabetes: adverse reactions occurring in $\geq 5\%$ of adult patients treated with BASAGLAR or Lantus products* over 24 weeks of treatment^{2,3}

	BASAGLAR + OAMs (n=376)	Lantus products* + OAMs (n=380)
Infection [†]	17%	16%
Nasopharyngitis	6%	6%
Upper respiratory tract infection	5%	4%

*Approved in the US or outside the US.

†Infections other than nasopharyngitis or upper respiratory tract infection.

‡Infections were a category of treatment-emergent adverse events that were reported during the 24-week trial and included events such as influenza, urinary tract infection, bronchitis, gastroenteritis, and sinusitis. Excluded were nasopharyngitis and upper respiratory tract infection.⁴

OAMs=oral anti-diabetic medications.

IMPORTANT NOTE ABOUT THESE RESULTS: BASAGLAR adverse reactions listed above are taken from the BASAGLAR US Prescribing Information.² The published ELEMENT 2 study reported 5.7% of patients taking BASAGLAR experienced nasopharyngitis and 4.5% upper respiratory tract infection.¹ These differences are due to rounding. Infections other than nasopharyngitis or upper respiratory tract infection were not reported in the publication. Adverse reactions may be reported and categorized differently within the publication compared with the BASAGLAR US Prescribing Information. Although these data were collected during the study, the adverse reactions from Lantus products (approved in the US or outside the US) listed above are not included in the BASAGLAR US Prescribing Information.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

BASAGLAR is contraindicated during episodes of hypoglycemia, and in patients with hypersensitivity to insulin glargine or one of its excipients.

WARNINGS AND PRECAUTIONS

BASAGLAR KwikPen[®] must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.

Please see Important Safety Information above and on page 4, and [Full Prescribing Information](#), including [Patient Information](#).

IMPORTANT SAFETY INFORMATION (cont'd)



WARNINGS AND PRECAUTIONS (cont'd)

Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously and only under close medical supervision, and the frequency of blood glucose monitoring should be increased. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.

Hypoglycemia is the most common adverse reaction associated with insulins, including BASAGLAR. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death.

Accidental mix-ups between another insulin glargine product (100 units/mL) and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors between BASAGLAR and other insulins, instruct patients to always check the insulin label before each injection.

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including BASAGLAR. If hypersensitivity reactions occur, discontinue BASAGLAR; treat per standard of care and monitor until symptoms and signs resolve. BASAGLAR is contraindicated in patients who have had hypersensitivity reactions to insulin glargine or one of the excipients.

All insulin products, including BASAGLAR, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated.

Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

ADVERSE REACTIONS

Adverse reactions commonly associated with insulin glargine products (5% or greater incidence) are: hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, rash, edema, and weight gain.

DRUG INTERACTIONS

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs and symptoms of hypoglycemia may be blunted when beta-blockers, clonidine, guanethidine, and reserpine are co-administered with BASAGLAR.

BV HCP ISI 24JUN2016

References: **1.** Rosenstock J, Hollander P, Bhargava A, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). *Diabetes Obes Metab.* 2015;17:734-741. **2.** Basaglar [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company. **3.** Data on file, Lilly USA, LLC. BAS20160408A. **4.** Data on file, Lilly USA, LLC. BAS20160811B.

For more information, please see [Full Prescribing Information](#), including [Patient Information](#).

BASAGLAR is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

Lantus is a registered trademark of sanofi-aventis U.S. LLC.

KwikPen is a registered trademark of Eli Lilly and Company.

06/2018 ©Lilly USA, LLC 2018. All rights reserved.

Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study)

J. Rosenstock¹, P. Hollander², A. Bhargava³, L. L. Ilag⁴, R. K. Pollom⁴, J. S. Zielonka⁴, W. J. Huster⁴
& M. J. Prince⁴

¹ Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA

² Baylor Endocrine Center, Dallas, TX, USA

³ Iowa Diabetes and Endocrinology Research Center, Des Moines, IA, USA

⁴ Eli Lilly and Company, Indianapolis, IN, USA

Aims: To compare the efficacy and safety of LY2963016 insulin glargine (LY IGLar) and the reference product (Lantus®) insulin glargine (IGlar) in combination with oral antihyperglycaemic medications in patients with type 2 diabetes (T2D).

Methods: This phase III, randomized, double-blind, 24-week study enrolled patients with T2D who were insulin-naïve [glycated haemoglobin (HbA1c) ≥ 7 and $\leq 11.0\%$] or previously on IGLar (HbA1c $\leq 11\%$) and treated with ≥ 2 oral antihyperglycaemic medications. Patients were randomized to receive once-daily LY IGLar ($n = 376$) or IGLar ($n = 380$) for 24 weeks. The primary efficacy outcome was to test the non-inferiority (0.4% and then 0.3% margin) of LY IGLar to IGLar, as measured by change in HbA1c from baseline to 24 weeks.

Results: Both treatment groups had similar and significant ($p < 0.001$) within-group decreases in mean HbA1c values from baseline. LY IGLar met non-inferiority criteria compared with IGLar for change in HbA1c from baseline [-1.29 vs -1.34% ; respectively, least-squares mean difference 0.052% (95% confidence interval -0.070 to 0.175); $p > 0.05$]. There were no treatment differences ($p > 0.05$) in fasting plasma glucose, proportion of patients reaching HbA1c $< 7\%$ or insulin dose at 24 weeks. Adverse events, allergic reactions, weight change, hypoglycaemia and insulin antibodies were similar between treatment groups. Similar findings were observed in patients who were insulin-naïve or previously treated with IGLar at baseline.

Conclusions: Both LY IGLar and IGLar, when used in combination with oral antihyperglycaemic medications, provided effective and similar glucose control with similar safety profiles in patients with T2D.

Keywords: LY2963016, insulin glargine, type 2 diabetes, insulin-naïve

Date submitted 13 February 2015; date of first decision 25 February 2015; date of final acceptance 27 April 2015

Introduction

Type 2 diabetes (T2D) is characterized by progressive deterioration and loss of β -cell function. Once oral therapy has become inadequate, the addition of basal insulin to an oral antihyperglycaemic medication regimen is often advised [1,2]. In patients with T2D, insulin glargine [IGlar; Lantus®, Sanofi-Aventis, Paris, France (rDNA origin)] has been shown to provide similar glycaemic control to that of NPH insulin, but with a lower risk of hypoglycaemia [3–7].

LY2963016 insulin glargine (LY IGLar) is the first biosimilar insulin approved for marketing authorization in the European Union (September 2014) [8]. This long-acting human insulin

analogue has an identical amino acid sequence and the same pharmaceutical form and strength, i.e. concentration of the active ingredient, as IGLar [9]. Biologicals that are approved based on similarity to an already marketed protein product (reference product) are sometimes referred to as 'biosimilars' (e.g. in the European Union and Japan) or using other terminology (e.g. 'subsequent entry biologics' in Canada) based on the applicable regulatory designation. In the USA, IGLar, the reference product for LY IGLar, was approved through the new drug application pathway [10] which necessitated the filing of LY IGLar through the 505(b)(2) regulatory pathway [11], and not the 351(k) biosimilar pathway [12]; therefore, LY IGLar is not considered to be a biosimilar in the USA. The development of a similar biological product (biosimilar) relies, in part, on the scientific knowledge gained from the reference product, provided that the active substance of the biosimilar has been demonstrated to be similar, in physicochemical and biological terms, to the active substance of the reference product [13]. Specific guidance from regulatory agencies outlines the data requirements for establishing similarity with a marketed biological

Correspondence to: Robyn K. Pollom, Lilly Corporate Center, Indianapolis, IN 46285, USA.
E-mail: pollomro@lilly.com

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

product [14–17]. The scientific principles in demonstrating the similarity of LY IGLar to IGLar are consistent with this guidance and with the requirements for demonstrating similarity between two biological products.

As part of the LY IGLar development programme that was designed to fulfill regulatory requirements, preclinical, phase I and phase III studies were performed. LY IGLar and IGLar were shown to have similar pharmacokinetic and pharmacodynamic properties [18–21]. In patients with type 1 diabetes (T1D), LY IGLar compared with IGLar, used in combination with insulin lispro, provided equivalent efficacy and a similar safety profile with no clinically meaningful differences [22].

The present manuscript reports on the phase III clinical trial that compared the efficacy and safety of LY IGLar and IGLar in combination with oral antihyperglycaemic medications in patients with T2D previously treated with insulin glargine or who were insulin-naïve.

Methods

Study Design and Patients

This phase III, randomized, multinational, multicentre, two-arm, active-controlled, double-blind, parallel study had a 24-week treatment period with a 4-week post-treatment follow-up in patients with T2D (Figure S1). The primary objective of the study was to show the non-inferiority of LY IGLar once daily to IGLar once daily, as measured by change in glycated haemoglobin (HbA1c), from baseline to 24 weeks, when used in combination with oral antihyperglycaemic medications. The study was conducted in accordance with the International Conference on Harmonisation Guidelines for Good Clinical Practice and the Declaration of Helsinki [23]. All patients provided written informed consent. The study was registered at Clinical.Trials.gov under the number NCT01421459. The ELEMENT 2 study investigators are listed in File S1.

Eligible study participants had T2D based on World Health Organisation diagnostic criteria [24], were aged ≥ 18 years, had been receiving ≥ 2 oral antihyperglycaemic medications at stable doses for 12 weeks before screening (with or without IGLar), had HbA1c levels ≥ 7.0 and $\leq 11.0\%$ if insulin-naïve or $\leq 11.0\%$ if previously on IGLar, and had a body mass index ≤ 45 kg/m². Exclusion criteria included treatment with pramlintide (Symlin[®]) or any other insulin except IGLar within the previous 30 days, treatment with a biosimilar insulin glargine within the previous 90 days, history of receiving basal-bolus therapy or, in the investigator's opinion, requirement for meal-time insulin to achieve target control, total daily insulin dose ≥ 1.5 U/kg, and more than one episode of severe hypoglycaemia within the past 6 months.

Treatment assignment was stratified on the basis of country, HbA1c value ($<8.5\%$ vs $\geq 8.5\%$), sulphonylurea use (yes or no), and time of basal insulin injection (daytime or evening/bedtime). Clinic visits occurred at screening, randomization (week 0) and weeks 2, 4, 8, 12, 16, 20 and 24. Patients randomized to treatment (LY IGLar or IGLar) were provided with covered insulin vials (for blinding purposes) and syringes during the study. The starting dose for all insulin-naïve patients was 10 U/day. Patients entering the study on IGLar

were randomized to either LY IGLar or IGLar at a dose equivalent to their prestudy IGLar dose. A patient-driven titration schedule of adding 1 unit daily until fasting plasma glucose (FPG) levels reached ≤ 5.6 mmol/l (100 mg/dl) was followed [25]; investigators had the discretion to decrease insulin dose for patients experiencing hypoglycaemia on their active dose while attempting to maintain the target FPG. It was anticipated that most of the titration would be largely completed during the titration period (weeks 0–12), with any further adjustments made after week 12 for safety concerns such as hypoglycaemia or unacceptable hyperglycaemia as determined by the investigator.

Outcomes

The HbA1c analyses were conducted by a central laboratory (Covance, Indianapolis, IN, USA) using the Variant II and Variant II Turbo HbA1c testing systems (Bio-Rad Laboratories, Hercules, CA, USA). Seven-point self-monitored blood glucose (SMBG) profiles (pre-meal for each meal, post-meal for breakfast and lunch, bedtime and 03:00 hours) were collected three times in the 2 weeks before each clinic visit and measured using study-provided glucometers (Accu-Chek Aviva\Performa; Roche, Indianapolis, IN, USA). Inpatient FPG variability was calculated based on the standard deviation of the morning pre-meal blood glucose value. Adverse events (AEs), defined as events that were reported as new or worsening in severity after randomization, were documented at every visit. Clinical chemistry and haematology panels were collected at baseline and week 24. Insulin antibodies were quantified as percent binding using a classic radioimmunoassay format. The anti-LY IGLar antibody assay has cross-reactivity to IGLar and human insulin; hence antibodies to LY IGLar and IGLar were measured using the same assay. During validation, an assay threshold of 0.26% bound/total was determined to indicate binding to LY IGLar. Sensitivity of the method was determined to be 25 ng/ml using a polyclonal affinity purified anti-insulin antibody assay.

Hypoglycaemia was defined as blood glucose ≤ 3.9 mmol/l (≤ 70 mg/dl) or a sign or symptom associated with hypoglycaemia. Nocturnal hypoglycaemia was defined as any hypoglycaemic event that occurred between bedtime and waking. Severe hypoglycaemia was defined as a hypoglycaemic event requiring the assistance of another person to actively administer treatment or other resuscitative actions. All severe hypoglycaemia episodes were reported as serious AEs (SAEs).

Other safety assessments included the special topic assessment of allergic reactions and injection site AEs. Injection site AEs were evaluated for pain, pruritus and rash associated with the injection, as well as the characteristics of the injection site (abscess, nodule, lipoatrophy, lipohypertrophy or induration). Allergic or immunological conditions were assessed by determining the frequency and severity of AEs from a prespecified list of AE terms.

Statistical Analyses

The non-inferiority design is in accordance with regulatory requirements [26–28]. Based on the primary objective, to show

non-inferiority of LY IGLar to IGLar at the 0.4% non-inferiority margin (NIM), and 0.3% NIM if the 0.4% NIM was met, 284 (568 total) completers per arm were needed at 24 weeks. This calculation assumed no treatment difference in HbA1c between LY IGLar and IGLar, a common standard deviation of 1.1% for change from baseline in HbA1c, 0.05 two-sided significance level and 90% power for a 0.3% NIM, and >99% power for a 0.4% NIM. Assuming a 15% dropout rate at 24 weeks, the required number of randomized patients was 334 per arm (668 total).

Analyses were conducted using SAS version 9.1.3 (SAS Drug Development, Cary, NC, USA) and were based on all patients who were randomized and took ≥ 1 dose of study drug, defined as the full analysis set, a slightly modified intent-to-treat population. If the measurement for a visit was missing, the previous non-missing measurement was analysed using the last-observation-carried-forward (LOCF) methodology. All tests of treatment effects were conducted at a two-sided α level of 0.05 and confidence intervals (CIs) were calculated as two-sided 95% CIs. All tests of interactions between treatment groups and other factors were conducted at a two-sided α level of 0.05. No adjustments for multiplicity were performed.

The primary efficacy measure was the change in HbA1c from baseline to the 24-week endpoint, defined as the value at 24 weeks or LOCF. The primary analysis model was an analysis of covariance (ANCOVA) for the change from baseline to endpoint with pooled country, sulphonylurea use (yes or no), time of basal insulin injection (daytime or evening/bedtime), and treatment as fixed effects and baseline HbA1c as a covariate. The primary treatment comparison was to compare LY IGLar with IGLar at the NIM of 0.4%. If the upper limit of the 95% CI on the change in HbA1c from baseline to the 24-week endpoint for LY IGLar versus IGLar was $<0.4\%$, then LY IGLar was declared non-inferior to IGLar. If the 0.4% NIM was met, then the upper limit of the 95% CI was compared with the 0.3% NIM. This gate-keeping procedure controlled the family-wise type 1 error rate at a one-sided 0.025 level.

A key secondary treatment comparison was to compare IGLar with LY IGLar at the NIM of -0.4% ; therefore, if LY IGLar was declared non-inferior to IGLar in the primary treatment comparison as described above, and IGLar was also declared non-inferior to LY IGLar in the secondary treatment comparison, then LY IGLar was considered to have equivalent efficacy to IGLar.

The analysis of the continuous secondary efficacy outcomes used the ANCOVA model which was used for the primary efficacy outcome. The proportion of patients achieving HbA1c target values (HbA1c <7.0 and $\leq 6.5\%$) during the study was analysed using Fisher's exact test. Hypoglycaemia rate, expressed as events per patient per year, was analysed using a negative binomial model with terms for treatment and other stratification variables.

A subgroup analysis of the HbA1c levels examined the consistency of the treatment effect for the subgroup defined by entry basal insulin treatment. The change in HbA1c from baseline to 24-week endpoint (LOCF) was analysed using ANCOVA with treatment, country, sulphonylurea use (yes or no), time of basal insulin injection (daytime or evening/bedtime) as

Table 1. Patient demographics and baseline characteristics.

	LY IGLar N = 376*	IGLar N = 380*
Age, years	59 \pm 10	59 \pm 10
<65 years, n (%)	264 (70)	278 (73)
Male, n (%)	179 (48)	199 (52)
Race, n (%)		
American Indian or Alaska Native	17 (5)	21 (6)
Asian	29 (8)	35 (9)
Black	26 (7)	32 (8)
Mixed race	2 (1)	1 (<1)
White	302 (80)	291 (77)
Body weight, kg	90 \pm 20	90 \pm 19
Body mass index, kg/m²	32 \pm 6	32 \pm 5
HbA1c		
%	8.34 \pm 1.09	8.31 \pm 1.06
mmol/mol	68 \pm 12	67 \pm 12
Entry HbA1c, n (%)		
<8.5% (<69 mmol/mol)	209 (56)	210 (55)
<7.0% (<53 mmol/mol)	19 (5)	25 (7)
FPG[†]		
mg/dl	159 \pm 45	160 \pm 44
mmol/l	8.82 \pm 2.50	8.86 \pm 2.42
Duration of diabetes, years	12 \pm 7	11 \pm 7
Basal insulin, n (%)		
IGLar	155 (41)	144 (38)
None	221 (59)	236 (62)
Time of basal insulin injection, n (%)		
Daytime	187 (50)	188 (50)
Evening/bedtime	189 (50)	192 (51)
Sulphonylurea use, n (%)	315 (84)	315 (83)

Data are mean \pm standard deviation, unless otherwise indicated. $p > 0.05$ for all treatment comparisons. FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; IGLar, insulin glargine; LY IGLar, LY2963016 insulin glargine; SMBG, self-monitored blood glucose.

*Full analysis set, N numbers reflect maximum sample size.

[†]By SMBG.

fixed effects and baseline HbA1c as a covariate, and the subgroup [i.e. entry basal insulin treatment (IGLar, none)], and subgroup-by-treatment interaction. Similar subgroup analyses were performed for other efficacy outcomes.

Results

Patients

Of the 756 patients included in the full analysis set population, 88% completed the 24-week treatment period. Patient decision (e.g. busy work schedule, relocation, family problems, fear of needles) was the most common reason for study discontinuation in both groups (Figure S2). The demographic characteristics of both treatment groups were well balanced (Table 1). In all, 621 patients (82.1%) were receiving two oral antihyperglycaemic medications before randomization, with significantly fewer patients in the LY IGLar group receiving two oral antihyperglycaemic medications compared with the IGLar group [LY IGLar: 298 patients (79.3%); IGLar: 323 patients (85.0%); $p = 0.046$]. The most common combinations of two oral antihyperglycaemic medications were metformin and sulphonylurea




Figure 1. (A) Change in absolute glycated haemoglobin (HbA1c) over 24 weeks. (B) Change from baseline HbA1c at 24 weeks LOCF. (C) Self-monitored blood glucose (SMBG) at baseline and 24 weeks LOCF. (D) Fasting plasma glucose over 24 weeks. Data are least squares means \pm standard error. Open circles: insulin glargine (IGlar); closed squares: LY2963016 insulin glargine (LY IGlAr). * $p = 0.04$ for treatment difference.

(62.4% of total patients), and dipeptidyl peptidase-4 inhibitors and metformin (10.1% of total patients). Analyses of baseline and demographic characteristics in the subgroups of patients previously on IGlAr and insulin-naïve at study entry, showed that all variables were balanced with the exception of race, where there was a greater proportion of white people in the LY IGlAr group than in the patients previously treated with IGlAr subgroup of the IGlAr group (Table S1).

Efficacy

Both treatment groups had within-group significant ($p < 0.001$) decreases in least squares (LS) mean HbA1c values from baseline, which began at visit 4 (week 6) and continued through to the 24-week endpoint (LOCF; Figure 1A). The primary efficacy outcome was met with the demonstration of non-inferiority of LY IGlAr to IGlAr on change in HbA1c from baseline to the 24-week endpoint at both the 0.4 and 0.3% NIMs. Non-inferiority of IGlAr to LY IGlAr at the same NIMs was also demonstrated (Figure 1B, Table 2). Collectively, the non-inferiority results indicate that LY IGlAr and IGlAr have equivalent efficacy. After adjustment for baseline differences for oral antihyperglycaemic medications and race, there were still no treatment differences for change in HbA1c at endpoint. At the 24-week endpoint (LOCF), the proportions of patients achieving the target HbA1c goals of <7.0 and ≤ 6.5 % were not significantly different between treatment groups (Table 2).

Figure 1C is a graphical summary of seven-point SMBG mean values for each time point at baseline and 24 weeks LOCF for both treatment groups. At endpoint (LOCF), the LS mean blood glucose value was lower in the LY IGlAr group compared with the IGlAr group at the morning 2-h postprandial time point (LY IGlAr, 8.07 mmol/L; IGlAr, 8.40 mmol/L; LS mean difference -0.33 mmol/L; $p = 0.050$), and significantly lower at the mid-day pre-meal time point (LY IGlAr, 6.81 mmol/L; IGlAr, 7.12 mmol/L; LS mean difference -0.31 mmol/L; $p = 0.040$). At all time points, improvements between baseline and endpoint (LOCF) were observed for both treatment groups. No statistically significant treatment differences were observed for any other time point at any visit or endpoint (LOCF). Both treatment groups had decreases in FPG from baseline to endpoint, and there were no statistically significant differences between treatment groups at any visit (Figure 1D). Additionally, there were no statistically significant differences between treatment groups in FPG variability at 24 weeks endpoint [LOCF; LS mean difference (standard error) 0.02 (0.06) mmol/L; $p = 0.788$].

Mean daily insulin dose was similar in both treatment groups at 24 weeks LOCF (Table 2). Patients in both treatment groups experienced weight gain of ~ 2 kg, with no statistically significant differences between treatment groups for change in body weight from baseline to endpoint (LOCF; Table 2).

A subgroup analysis for select efficacy endpoints by entry basal insulin treatment (IGlar, none) found no significant treatment-by-entry basal insulin treatment interaction for

Table 2. Clinical assessments at study endpoint.

	LY IGl ^a N = 376*	IGlar N = 380*
HbA1c (%)		
Endpoint	7.04 ± 0.06	6.99 ± 0.06
Change from baseline	-1.29 ± 0.06	-1.34 ± 0.06
LS mean difference (95% CI)	0.052 (-0.070, 0.175)	
HbA1c, mmol/mol		
Endpoint	53 ± 1	53 ± 1
Change from baseline	-14 ± 1	-15 ± 1
LS mean difference (95% CI)	0.6 (-0.8, 1.9)	
Target HbA1c, n (%)		
<7.0% (<53 mmol/mol)	180 (49)	197 (53)
≤6.5% (≤48 mmol/mol)	99 (27)	114 (30)
FPG[†](change from baseline)		
mg/dl	-48 ± 3	-46 ± 3
mmol/l	-2.64 ± 0.17	-2.58 ± 0.17
Insulin dose, U/kg/day		
	0.50 ± 0.03	0.48 ± 0.03
Hypoglycaemia rate overall[‡] mean ± s.d.		
Total	21.3 ± 24.4	22.3 ± 28.2
Nocturnal [§]	7.6 ± 11.8	8.1 ± 14.6
Severe	0.04 ± 0.66	0.01 ± 0.16
Weight change, kg		
	1.8 ± 0.3	2.0 ± 0.3
Patients with detectable antibodies overall[¶] n (%)		
% insulin antibody binding at 24 weeks (median)	1.07	0.65

Data are LS mean ± standard error, unless otherwise indicated and from LOCF, unless otherwise indicated. $p > 0.05$ for all treatment comparisons. CI, confidence interval; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; IGlar, insulin glargine; LOCF, last observation carried forward (endpoint); LS, least squares; LY IGl^a, LY2963016 insulin glargine; s.d., standard deviation; SMBG, self-monitored blood glucose.

*Full analysis set, N numbers reflect maximum sample size.

[†]By SMBG.

[‡]Events/patient/1 year. The overall rate at 24 weeks accounts for all events reported during the 24-week treatment period.

[§]Including events with blood glucose ≤70 mg/dl.

[¶]Measured for the overall 24-week treatment period and not at LOCF.

change in HbA1c from baseline to endpoint (LOCF), for change in FPG from baseline to endpoint (LOCF), for weight change, or for insulin dose at endpoint, indicating no significant differential treatment effect on these efficacy endpoints for patients entering the study on IGlar and for insulin-naïve patients (Table 3).

Safety

There were no significant differences between treatment groups for the rate of each category of hypoglycaemia (total, nocturnal and severe), adjusted for 1 year, at 24 weeks (Table 2). The rate of documented symptomatic hypoglycaemia blood glucose ≤70 mg/dl (≤3.9 mmol/l) at 24 weeks was also similar ($p = 0.935$) between treatment groups. Similarly, there were no significant treatment differences in the incidence of total hypoglycaemia for 24 weeks (LY IGl^a 79%; IGlar 78%; $p = 0.594$), in the incidence of nocturnal hypoglycaemia for 24 weeks (LY IGl^a 57%; IGlar 54%; $p = 0.462$), and in the incidence of severe

hypoglycaemia for 24 weeks (LY IGl^a <1%; IGlar <1%). A subgroup analysis for hypoglycaemia by entry basal insulin treatment (IGlar, none) showed no significant treatment-by-entry basal insulin treatment interaction on the rate of any category of hypoglycaemia for patients entering the study on IGlar, or insulin-naïve patients (Table 3).

Table 4 provides an overview of AEs reported during the 24-week study for the full analysis set population. The incidences of AEs and SAEs reported for LY IGl^a were similar to those for IGlar. The most frequently reported AEs were nasopharyngitis (5.7%), upper respiratory tract infection (4.5%) and diarrhoea (3.0%). There were two deaths during the study, one as a result of myocardial infarction (IGlar) and one as a result of lung adenocarcinoma (LY IGl^a); neither was considered by the investigator to be related to the study drug. The incidence of allergic reactions was similar among treatment groups; most events were mild or moderate in severity and none led to discontinuation (Table 4). The incidence of injection site AEs was similar between treatment groups; most patients reporting injection site AEs reported having mild or moderate pain associated with the injection (Table 4). A total of 96 patients (13.2%) had detectable antibodies to insulin, and there were no statistically significant treatment differences (Table 2). In addition, there was no statistically significant difference between treatment groups in median insulin antibody-binding values observed at 24-weeks (LOCF; Table 2). No clinically meaningful baseline to endpoint changes in any laboratory values were identified within or between groups (data not shown).

Discussion

Because of the complex structure of biologics and the distinct manufacturing processes involved in their production, LY IGl^a must be shown to have similar physicochemical and biological characteristics and a similar safety and efficacy profile to those of the reference product, IGlar, in order to gain regulatory approval [13]. Minor differences between the biosimilar and reference drug in clinically inactive components may occur and there should be no clinically meaningful differences in terms of safety, purity and potency [29]. In the present phase III clinical trial, we evaluated the efficacy and safety of LY IGl^a versus IGlar in patients with T2D.

Non-inferiority of LY IGl^a to IGlar, as measured by change in HbA1c from baseline to the week 24 endpoint, when used in combination with oral antihyperglycaemic medications, was shown at the NIM of 0.3%, meeting regulatory requirements [26–28]. Both treatment groups had statistically significant within-group decreases in HbA1c from baseline to the 24-week endpoint. LY IGl^a and IGlar resulted in similar lowering of blood glucose levels by SMBG from baseline to week 24 of the study, with similar changes in insulin dose and weight between treatment groups. The safety profiles for LY IGl^a and IGlar were similar and LY IGl^a was well tolerated. Similar safety and efficacy results were seen in subgroup analyses of patients entering the study on previous IGlar versus insulin-naïve patients.

The present study did not show any significant differences in safety measures between the treatment groups. The incidence and rate of hypoglycaemia for any category of hypoglycaemia

Table 3. Clinical assessments at study endpoint for patients who entered the study on insulin glargine and insulin-naïve patients.

	Insulin-naïve		Prior IGLar	
	LY IGLar N = 220*	IGlar N = 235*	LY IGLar N = 155*	IGlar N = 144*
HbA1c, %				
Endpoint HbA1c	6.86 ± 0.07	6.79 ± 0.07	7.31 ± 0.08	7.32 ± 0.08
Change from baseline	-1.48 ± 0.07	-1.54 ± 0.07	-1.02 ± 0.08	-1.01 ± 0.08
LS mean difference (95% CI)	0.061 (-0.091, 0.214)		-0.004 (-0.193, 0.185)	
HbA1c, mmol/mol				
Endpoint HbA1c	51 ± 1	51 ± 1	56 ± 1	56 ± 1
Change from baseline	-16 ± 1	-17 ± 1	-11 ± 1	-11 ± 1
LS mean difference (95% CI)	0.7 (-1.0, 2.3)		-0.1 (-2.1, 2.0)	
Target HbA1c, n (%)				
<7% (<53 mmol/mol)	117 (54)	139 (60)	63 (41)	58 (41)
≤6.5% (≤48 mmol/mol)	65 (30)	86 (37)	34 (22)	28 (20)
FPG†(change from baseline)				
mg/dl	-57 ± 3	-56 ± 3	-34 ± 4	-30 ± 4
mmol/l	-3.16 ± 0.19	-3.09 ± 0.19	-1.86 ± 0.22	-1.68 ± 0.22
Insulin dose, U/kg/day				
	0.42 ± 0.03	0.44 ± 0.03	0.60 ± 0.03	0.53 ± 0.03
Hypoglycaemia rate overall‡ mean ± s.d.				
Total	21.6 ± 25.6	22.9 ± 27.4	20.8 ± 22.7	21.5 ± 29.6
Nocturnal§	6.7 ± 10.7	7.6 ± 12.5	8.5 ± 13.1	8.8 ± 17.5
Severe (n = 2)	(n = 2)	(n = 2)	—	—
Weight change, kg				
	2.0 ± 0.3	2.2 ± 0.3	1.4 ± 0.3	1.7 ± 0.3

Data are LS mean ± standard error, unless otherwise indicated, and from LOCF, unless otherwise indicated. $p > 0.05$ for all treatment comparisons and subgroup-by-treatment interactions. FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; IGLar, insulin glargine; LOCF, last observation carried forward (endpoint); LS, least squares; LY IGLar, LY2963016 insulin glargine; s.d., standard deviation; SMBG, self-monitored blood glucose.

*Full analysis set, N numbers reflect maximum sample size.

†By SMBG.

‡Events/patient/1 year. The overall rate at 24 weeks accounts for all events reported during the 24-week treatment period.

§Including events with blood glucose ≤70 mg/dl.

were similar between the treatment groups. Adverse events reported for LY IGLar were similar to those for IGLar and were consistent with the AE profile reported in studies assessing efficacy and safety of IGLar in adult patients with T1D and T2D [30,31]. The incidences of allergic reactions and of injection site AEs were low and similar between the treatment groups. The proportion of patients with detectable anti-insulin antibodies was low and consistent with previous findings in patients with T2D [6]. Finally, median antibody percent binding was similar between treatment groups at endpoint.

The double-blind design strengthened the present study. Blinding eliminates the possibility of investigator bias and participant bias, which could affect dose titration, AE and hypoglycaemia reporting, making conclusions regarding efficacy and safety more straightforward and reliable. Another strength of this study was the inclusion of both insulin-naïve patients and previous IGLar users, which enabled us to make informative observations in both types of patients. Although randomization was not stratified by prestudy basal insulin status, the number of patients who were insulin-naïve or who were previous IGLar users was balanced between the treatment groups. For the primary and secondary objectives, data were not analysed separately because the study was powered to demonstrate non-inferiority based on the total number of patients, inclusive of both insulin-naïve and previous IGLar users; however, because there was interest in possible differential treatment effects for patients who were insulin-naïve and those

who were previous IGLar users, subgroup analyses were performed to assess the consistency of the treatment effect on outcomes. There were no treatment-by-subgroup interactions for change in HbA1c from baseline to endpoint, indicating no significant differential treatment effects on the change in HbA1c across the subgroups; however, not surprisingly, baseline HbA1c was lower in the group previously treated with IGLar versus the insulin-naïve group, and the improvement in HbA1c was greater in the insulin-naïve versus the group previously treated with IGLar. No significant differential treatment effects in these subgroups were seen in other endpoints including proportion of patients reaching target HbA1c, FPG, insulin dose, hypoglycaemia rate and weight change. The observed responses and outcomes in both treatment groups were generally consistent with findings in other studies of insulin-naïve and previously insulin-treated patients with T2D treated with insulin glargine [3,6,32], although to our knowledge, no studies to date have examined endpoints in these subgroups within the same study.

While the duration of the present study was shorter, the findings are consistent with the ELEMENT 1 study, which showed LY IGLar's similarity with IGLar with repeated once-daily dosing, over 24 and up to 52 weeks, in patients with T1D [22].

In conclusion, both LY IGLar and IGLar, when used in combination with ≥2 oral antihyperglycaemic medications, provided effective glucose control with similar safety profiles in patients with T2D. The results of this double-blind, treat-to-target

Table 4. Adverse events, allergic reactions and injection-site reactions.

AEs*	LY IGl [†] N = 376 [†]	IGlar N = 380 [†]
Deaths	1 (<1)	1 (<1)
SAEs	15 (4)	18 (5)
Discontinuations due to an AE	6 (2)	11 (3)
Injection site AE	13 (4)	11 (3)
AEs	196 (52)	184 (48)
AE possibly related to study drug	26 (7)	23 (6)
AE possibly related to study procedure	6 (2)	8 (2)
AE possibly related to study disease state (diabetes)	19 (5)	18 (5)
Special topic assessment of allergic reactions	21 (6)	27 (7)
Pruritus, rash, dermatitis, other‡	8 (2)	12 (3)
Arthralgia, peri-arthritis	7 (2)	9 (2)
Injection site (reaction, pruritus, induration)	5 (1)	4 (1)
Asthma, nasal oedema	3 (1)	5 (1)
Injection site reaction (patient questionnaires)	13 (4)	11 (3)
Pain	10 (3)	5 (1)
Pruritus	4 (1)	4 (1)
Rash	3 (1)	3 (1)

Data are n (%). $p > 0.05$ for all treatment comparisons [with the exception of injection site reactions (patient questionnaires) where treatment comparisons were not performed]. AE, adverse event; IGl[†], insulin glargine; LY IGl[†], LY2963016 insulin glargine; SAE, serious adverse event.

*Patients may be counted in >1 category.

[†]Full analysis set, N numbers reflect maximum sample size.

[‡]Angioedema, macular rash, papular rash, pruritic rash, vesicular rash.

clinical trial showing effective glucose-lowering and similar safety and efficacy profiles for LY IGl[†] and IGl[†] in the total study population, as well as in both insulin-naïve and previously insulin-treated subgroups of patients with T2D, add to the totality of the evidence showing the similarity of LY IGl[†] to IGl[†]. LY IGl[†] provides a well-tolerated and effective once-daily basal insulin option for treatment of patients with T2D in combination with oral agents.

Acknowledgements

This study was funded by Eli Lilly and Company and Boehringer-Ingelheim. The authors wish to acknowledge the investigators and patients who participated in this study and Michelle Carey PhD of inVentiv Health Clinical for assistance with the preparation of this manuscript. This work was previously published as an abstract presented at the American Diabetes Association's 74th Scientific Sessions, San Francisco, CA, June 2014 (64-OR) and the European Association for the Study of Diabetes 50th Annual Meeting, Vienna, Austria, September 2014 (A948).

Conflict of Interest

J. R. has served on scientific advisory panels, served as a consultant and received research support from insulin manufacturers Eli Lilly and Company, Sanofi and Novo Nordisk. P. H. has served on scientific advisory panels for Johnson & Johnson, Merck, Novo Nordisk and Roche Pharmaceuticals. A. B. has received research support from Abbvie, AstraZeneca

Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc., Duke Clinical Research Institute, Eli Lilly and Company, Halozyme Therapeutics, Jaeb, Mylan, Novo Nordisk Inc., Orexigen Therapeutics Inc., Sanofi-Aventis, University of Oxford. L. L. I., W. J. H., J. S. Z., R. K. P. and M. J. P. are employees of and hold stock in Eli Lilly and Company.

J. R., P. H. and A. B. contributed to the interpretation and discussion of the research, participated in conducting the study and reviewed and edited the manuscript. W. J. H. participated in the study design, designed and conducted the statistical analyses, participated in the interpretation and discussion of the research and in writing the manuscript. L. L. I., J. S. Z., R. K. P. and M. J. P. participated in the study design, in conducting the study, in the data analysis, in the interpretation and discussion of the research, and in writing the manuscript. All authors approved the version to be published. R. K. P. is the guarantor of this work and, as such takes full responsibility for the work as a whole, including the study design, access to data, and the decision to submit and publish the manuscript. M. C. (non-author) prepared the draft manuscript and provided editorial support.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Figure S1. Study design. IGl[†], insulin glargine; LY IGl[†], LY2963016 insulin glargine; OAMs, oral antihyperglycaemic medications; QD, once-daily administration. *Telephone visits.

Figure S2. Patient disposition. IGl[†], insulin glargine; LY IGl[†], LY2963016 insulin glargine.

File S1. List of ELEMENT 2 investigators.

Table S1. Patient demographics and baseline characteristics for patients who entered the study on insulin glargine and for insulin-naïve patients.

References

- Niswender K. Early and aggressive initiation of insulin therapy for type 2 diabetes: what is the evidence? *Clin Diabetes* 2009; **27**: 60–68.
- Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia* 2012; **55**: 1577–1596.
- Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. *Diabetes Care* 2003; **26**: 3080–3086.
- Rosenstock J, Dailey G, Massi-Benedetti M et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. *Diabetes Care* 2005; **28**: 950–955.
- Rosenstock J, Fonseca V, Schinzel S et al. Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. *J Diabetes Complications* 2014; **28**: 742–749.
- Yki-Jarvinen H, Dressler A, Ziemer M, HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. *Diabetes Care* 2000; **23**: 1130–1136.

7. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. *Diabetologia* 2006; **49**: 442–451.
8. European Medicines Agency. Abasaglar (previously Abasria). 2014. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/002835/human_med_001790.jsp&ftmid=WC0b01ac058001d124. Accessed 31 March 2015.
9. European Medicines Agency. European public assessment report: Abasria. 2014. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002835/WC500175383.pdf. Accessed 31 March 2015.
10. Food and Drug Administration. Drug approval package: Lantus (insulin glargine [rDNA origin]) NDA #21-081. 2000. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21081_Lantus.cfm. Accessed 31 March 2015.
11. Eli Lilly and Company. FDA grants tentative approval for Lilly and Boehringer Ingelheim's Basaglar™ (insulin glargine injection). 2014. Available from URL: <https://investor.lilly.com/releasedetail.cfm?ReleaseID=866751>. Accessed 31 March 2015.
12. Food and Drug Administration. Biologics Price Competition and Innovation Act. 2009. Available from URL: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf>. Accessed 31 March 2015.
13. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). 2014. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500167838.pdf. Accessed 31 March 2015.
14. European Medicines Agency. Committee for medicinal products for human use. Guideline on similar biological medicinal products. 2005. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf. Accessed 31 March 2015.
15. European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues. 2014. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/04/WC500165988.pdf. Accessed 31 March 2015.
16. Food and Drug Administration. Guidance for industry: clinical pharmacology data to support a demonstration of biosimilarity to a reference product. 2014. Available from URL: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM397017.pdf>. Accessed 31 March 2015.
17. World Health Organization. Expert committee on biological standardization. Guidelines on evaluation of Similar Biotherapeutic Products (SBPs). 2009. Available from URL: http://www.who.int/biologicals/areas/biological_therapeutics/BIO_THERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed 31 March 2015.
18. Byrd RA, Blackbourne JL, Schultze AE, Vahle JL. Comparative subchronic toxicity studies in rats of LY2963016 (LY), an insulin glargine product, with USA sourced Lantus® (US-L) and EU-sourced Lantus® (EU-L). *Toxicologist* 2014; **138**: 1650.
19. Heise T, Zhang X, Quin Lam EC et al. Duration of action of 2 insulin glargine products, LY2963016 and Lantus®, in subjects with type 1 diabetes mellitus (T1DM). *Diabetes* 2014; **63**(Suppl. 1): 891-P.
20. Linnebjerg H, Quin Lam EC, Seger ME et al. Comparative pharmacokinetics (PK) and pharmacodynamics (PD) of LY2963016 insulin glargine and EU- and U.S.-approved versions of Lantus® insulin glargine in healthy subjects. *Diabetes* 2014; **63**(Suppl. 1): 889-P.
21. Zhang X, Quin Lam EC, Seger ME et al. Comparative pharmacokinetics and pharmacodynamics of two insulin glargine products, LY2963016 and Lantus®, in healthy subjects at two dose levels. *Diabetes* 2014; **63**(Suppl. 1): 890-P.
22. Blevins TC, Dahl D, Rosenstock J et al. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomised controlled trial (The ELEMENT 1 Study). *Diabetes, Obesity and Metabolism* 2015; **17**: 726–733.
23. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. *JAMA* 1997; **277**: 925–926.
24. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. 1999. Available from URL: http://apps.who.int/iris/bitstream/10665/66040/1/WHO_NCD_NCS_99.2.pdf?ua=1. Accessed 15 October 2014.
25. Gerstein HC, Yale JF, Harris SB et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. *Diabet Med* 2006; **23**: 736–742.
26. European Medicines Agency. Guideline on the choice of the non-inferiority margin. 2005. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003636.pdf. Accessed 15 October 2014.
27. Food and Drug Administration. Guidance for industry: diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. Draft guidance February 2008. Available from URL: <http://www.fda.gov/downloads/Drugs/Guidances/ucm071624.pdf>. Accessed 1 April 2015.
28. Food and Drug Administration. Guidance for industry: non-inferiority clinical trials. Draft guidance March 2010. 2010. Available from URL: <http://www.fda.gov/downloads/Drugs/.../Guidances/UCM202140.pdf>. Accessed 1 April 2015.
29. Food and Drug Administration. Guidance for industry: Quality considerations in demonstrating biosimilarity to a reference protein product. 2012. Available from URL: <http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf>. Accessed 26 March 2015.
30. LANTUS- insulin glargine injection, solution. Drug label information. 2015. Available from URL: <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5e07a0c-7e14-4756-9152-9fea485d654a>. Accessed 1 April 2015.
31. European Medicines Agency. LANTUS: EPAR – Product information. 2015. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000284/WC500036082.pdf. Accessed 1 April 2015.
32. Meneghini L, Atkin SL, Gough SC et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. *Diabetes Care* 2013; **36**: 858–864.